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Introduction
Reports of large trials of breast cancer conﬁ  rm the value 
of aromatase inhibitors as adjuvant systemic therapy for 
postmenopausal women with endocrine-responsive early 
breast cancer [1-9]. Th   e inclusion of an aromatase inhibi-
tor in the adjuvant treatment program for this population 
has been recommended by both the American Society of 
Clinical Oncology and St. Gallen guidelines [10,11]. 
Studies have shown that 5 years of adjuvant therapy with 
an aromatase inhibitor alone improved disease-free 
survival (DFS) and time to distant recurrence (TDR) in 
comparison with 5 years of tamoxifen in this population 
[1-3,12], and recently the Breast International Group 
(BIG) 1-98 trial showed improved overall survival (OS) 
with the aromatase inhibitor letrozole [13]. Other studies 
have shown that switching to an aromatase inhibitor after 
2 years of tamoxifen improves outcome [4-8]. Results 
were conﬁ  rmed in an overview analysis [9].
Th  e BIG 1-98 study is a double-blind, four-arm trial 
comparing 5 years of monotherapy with tamoxifen or 
with letrozole or with sequences of 2 years of one of these 
agents followed by 3 years of the other (Figure 1). Centers 
participated in one of two randomization options (two-
arm or four-arm). Between 1998 and 2003, 8,010 patients 
were enrolled. Th  e trial is designed to answer two 
questions concerning how best to use endocrine agents 
for the treatment of early breast cancer in post  meno-
pausal women with hormone receptor-positive tumors, 
the ﬁ   rst to compare letrozole monotherapy with 
tamoxifen monotherapy and the second to determine the 
beneﬁ  t of letrozole in sequence with tamoxifen. Table 1 
presents a summary of the study subpopulations contri-
buting to various data analyses of eﬃ   cacy questions. In 
BIG 1-98, the primary endpoint is DFS, deﬁ  ned as the 
time from random assignment to the earliest time of 
invasive recurrence in local, regional, or distant sites; a 
new invasive breast cancer in the contralateral breast; 
any second (non-breast) malignancy; or death from any 
cause. Secondary outcomes are OS, TDR, and safety 
[14,15].
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© 2011 BioMed Central LtdPatients were seen for follow-up at clinic visits every 
6 months during treatment to gather general safety data, 
to document predeﬁ  ned toxicity data, and to receive a 
new supply of study medications. Survival, disease status, 
and cardiac, bone, and endometrial adverse events (AEs) 
were reported every 6 months for 5 years from random 
assignment and were followed by yearly reports after 
5 years.
Various aspects of the results of BIG 1-98 have been 
published in separate papers in the past 5 years. Th  e 
purpose of the present review is to bring the various 
results together in one place to give an overall inter  pre-
tation of their signiﬁ  cance for science and patient care.
Letrozole versus tamoxifen
Th  e ﬁ  rst report of the results of the BIG 1-98 trial was 
based on the primary core analysis, which was published 
in 2005 [1]. Th   is analysis included all 8,010 patients but 
did not include any events after the ﬁ  rst 2 years (the time 
of the switch) for patients in the two sequential arms. Th  e 
results of the primary core analysis showed that letrozole 
improved DFS and TDR in comparison with tamoxifen 
alone. After a median follow-up of 25.8 months, 5-year 
DFS estimates were 84.0% and 81.4%, respectively. As 
compared with tamoxifen, letrozole signiﬁ  cantly reduced 
the risk of a DFS event (hazard ratio (HR) = 0.81, 95% 
conﬁ  dence interval (CI) 0.70 to 0.93; P = 0.003) and the 
risk of distant recurrence (HR = 0.73, 95% CI 0.60 to 0.88; 
P = 0.001).
For a report early in follow-up (when most of the 
observed events occurred within the ﬁ  rst 2 years), the 
primary core analysis was appropriate, but for future 
updates, which are inﬂ   uenced substantially by events 
beyond 2 years, only those patients randomly assigned to 
the monotherapy arms (4,922 patients from both two-
arm and four-arm options) are included in the head-to-
head comparison of 5 years of letrozole versus tamoxifen 
[2,13,14]. Th  e  ﬁ  rst results of the trial restricted to patients 
in the two monotherapy groups were published in 2007 
[2]. At a median follow-up time of 51 months, results 
conﬁ   rmed the earlier report,  showing improved DFS 
(5-year DFS rates of 84.0% and 81.1% for letrozole and 
Figure 1. Design of the Breast International Group 1-98 trial. The design allows both head-to-head comparison of letrozole monotherapy 
versus tamoxifen monotherapy (4,922 patients) and assessment of the role of sequential endocrine treatments (6,182 patients). Neoadj CT, 
neoadjuvant chemotherapy.
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Table 1. Summary of study populations in the Breast International Group 1-98 trial
   Number  of
Population patients  Comments
Intention-to-treat population  8,010  Eighteen randomly assigned patients withdrew consent to participate before starting treatment.
  Two-arm randomization option  1,828 
  Four-arm randomization option  6,182 
Primary core analysis population  8,010  Follow-up for two sequential treatment groups is censored at 2 years (time of treatment switch).
Monotherapy population  4,922  Patients were randomly assigned to receive 5 years of tamoxifen alone or letrozole alone. 
  Two-arm randomization option  1,828 
  Four-arm randomization option  3,094 
Sequential treatment analysis population   6,182  Patients in the intention-to-treat population enrolled in the four-arm randomization option.
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Page 2 of 16tamoxifen, respectively) (HR = 0.82, 95% CI 0.71 to 0.95; 
P = 0.007) and improved TDR (HR = 0.81, 95% CI 0.67 to 
0.98; P = 0.03) with letrozole compared with tamoxifen. 
Th   e monotherapy comparison was updated in 2010, after 
all patients had completed 5 years of trial treatment [13], 
and is discussed below.
Selective crossover on the tamoxifen monotherapy 
arm
In 2005, the presentation of the ﬁ  nding that letrozole 
signiﬁ  cantly reduced both distant recurrences and DFS 
events compared with tamoxifen led to the decision to 
inform patients in the tamoxifen monotherapy group of 
their treatment assignment. ‘Selective crossover’ in this 
trial refers to the act of choosing to switch from 
tamoxifen monotherapy to letrozole prior to completion 
of 5 years of tamoxifen, after the results were known in 
2005. While selective crossover is often in the best 
interest of patients, it complicates later trial analyses with 
further patient follow-up because the randomized, 
blinded trial design is compromised. Th  rough  a  protocol 
amendment, women who were randomly assigned to 
tamoxifen alone and who were disease-free could receive 
letrozole. Of 2,459 patients in the tamoxifen-alone treat-
ment arm, 619 (25.2%) selectively crossed over to letro-
zole. Th   e crossing over of 25% of patients from the less 
eﬀ   ective to the more eﬀ   ective regimen called into 
question whether the intention-to-treat (ITT) analysis, 
which ignores the crossover, will give the most clinically 
relevant updated estimate of the relative treatment eﬀ  ect.
Selective crossover represents a special case of non-
adherence to a randomized treatment following the 
report of positive trial results. Speciﬁ  cally, control group 
patients are oﬀ  ered and accept the opportunity to cross 
over to the experimental treatment. Selective crossover is 
distinct from a protocol-deﬁ  ned treatment switch or ad 
hoc non-adherence to a random assignment because the 
crossover is motivated by randomized evidence that the 
experimental treatment is more eﬀ  ective. Th   us, the ITT 
control group subject to selective crossover is likely to 
have a better outcome than if the control group had 
continued to receive the randomized treatment. Selective 
crossover disturbs the randomized comparison in 
updated analyses performed subsequent to ﬁ  rst results 
and therefore particularly impacts the OS results, which 
require longer follow-up.
With selective crossover and further follow-up, the 
treatment received by patients in the tamoxifen control 
arm in BIG 1-98 becomes a mix of the control and 
experimental treatments. With the potential for selection 
bias among the patients who decide to cross over, the 
beneﬁ   ts of random assignment erode and the trial 
becomes a hybrid of a randomized trial and observational 
study. For a randomized clinical trial, the ITT analysis is 
the ‘gold standard’ analytic approach designed to control 
bias. However, external evidence from a meta-analysis of 
similar trials [9] shows that the estimated outcomes of 
the tamoxifen arm in the ITT analysis are likely to be 
better than if the trial had not been amended and all 
patients randomly assigned to tamoxifen continued to 
receive the drug for 5 years. As the selective crossover 
transforms the randomized trial toward an observational 
study, established modeling methods to address issues of 
bias due to treatment selection are needed. For the BIG 
1-98 study, the methodology called inverse probability of 
censoring weighted (IPCW) analysis is used to clarify the 
clinical beneﬁ   t of letrozole compared with tamoxifen 
[13]. Th   e IPCW analysis estimates the clinical beneﬁ  t of 
letrozole versus tamoxifen which would have been ob-
served had there been no selective crossover in the trial. 
An editorial accompanying the manuscript conﬁ  rmed 
the appropriateness of this method and discussed the 
interpretation of the IPCW results in the trial speciﬁ  cally 
and cancer trials more broadly [16].
Monotherapy comparison using inverse 
probability of censoring weighted analysis
IPCW is a well-established approach in randomized and 
observational studies to overcome selection biases. Th  e 
method is one of several approaches to causal inference 
and analyzes only the available data under conditions of 
‘informative’ missing data. Speciﬁ   cally, we employed 
IPCW Cox modeling [17]. In the setting of selective 
cross  over, IPCW modeling artiﬁ  cially creates a scenario 
of ‘missing’ follow-up data by censoring the follow-up of 
each woman at the time she crossed over (‘informative’ 
censoring). However, the truncated follow-up is ‘re-
created’ by applying weighting to the follow-up of women 
who have similar demographic and disease characteristics 
and who did not cross over. In this way, the follow-up of 
women who remain on tamoxifen accounts not only for 
themselves in the analysis but also for comparable 
women whose experience remaining on tamoxifen can  not 
be observed, because they selectively changed treatments.
In the IPCW monotherapy analysis, we analyzed the 
data set of the protocol-speciﬁ  ed update at 10 years after 
trial initiation [12] and took into consideration the 
selective crossover. After follow-up was truncated, the 
median follow-up was reduced to 74 months (IPCW) 
from 76 months (ITT).
Weighted Cox models, using IPCW, estimated a 
statistically signiﬁ  cant, 18% reduction in the hazard of an 
OS event with letrozole treatment (HR = 0.82, 95% CI 
0.70 to 0.95). IPCW estimates of 5-year OS were 91.8% 
and 90.4% for letrozole and tamoxifen, respectively. Th  e 
IPCW HRs of DFS and TDR events were 0.83 (95% CI 
0.74 to 0.94) and 0.80 (95% CI 0.67 to 0.94), respectively 
(Figure 2). Th   e results show that adjuvant treatment with 
Regan et al. Breast Cancer Research 2011, 13:209 
http://breast-cancer-research.com/content/13/3/209
Page 3 of 16letrozole, compared with tamoxifen, signiﬁ  cantly reduces 
the risk of death, the risk of recurrent disease, and the 
risk of recurrence at distant sites in postmenopausal 
women with hormone receptor-positive breast cancer. 
Th  e OS results were consistent in most subgroups 
(Figure 2).
Sequential treatment comparisons
Th   e analysis of the sequential treatments was limited to 
the 6,182 patients entered into the four-arm option 
(Figure 1). Th   e sequential treatment analysis was pub  lished 
in 2009 [12], with emphasis on comparing the two 
letrozole-containing sequential regimens with letrozole 
monotherapy from the time of random assignment; the 
three letrozole-containing regimens had remained blinded. 
Th   e tamoxifen monotherapy regimen was already shown 
to be less eﬀ  ective than letrozole, had been unblinded, 
and therefore was not included in the eﬃ   cacy 
comparisons. Tamoxifen was, however, included in AE 
comparisons with the other three regimens.
At a median follow-up of 71 months from random 
assign  ment, neither tamoxifen followed by letrozole 
Figure 2. Inverse probability of censoring weighted Cox model results of the comparison of the monotherapy arms of Breast 
International Group 1-98 at median follow-up of 74 months. Comparisons for (a) primary and secondary endpoints and (b) subgroups with 
overall survival (OS) endpoint are shown. The size of the boxes is inversely proportional to the standard errors of the hazard ratio. The solid vertical 
line is placed at 0.82, which is the hazard ratio estimate for the overall analysis of the OS endpoint. *Other includes ER+/PgR unknown, ER unknown/
PgR+, ER-/PgR- (ineligible), ER-/PgR unknown, and ER unknown/PgR unknown. CI, confi  dence interval; ER, estrogen receptor; L, letrozole; Nx, 
regional lymph nodes not examined; PgR, progesterone receptor; T, tamoxifen. Reprinted with permission from the Journal of Clinical Oncology [13]. 
Copyright 2011, American Society of Clinical Oncology.
A End Point Analysis (N=4,922)
B Subgroup Analysis (OS)
Favors Letrozole Favors Tamoxifen
1.00 1.50 0.50 0.75 1.25
Favors Letrozole Favors Tamoxifen
1.00 1.50 0.50 0.75 1.25
Hazard Ratio Events 95% CI  Interaction P
Tumor size > 2 cm (n=1,859) 177 L, 198 T 0.84 0.69 to 1.03
Tumor size  2 cm (n=3,019) 124 L, 138 T 0.80 0.62 to 1.01 0.90
Peritumoral vessel invasion absent (n=3,599)
Peritumoral vessel invasion present (n=854)
186 L, 214 T
82 L, 91 T 0.80
0.80 0.66 to 0.98
0.59 to 1.08
Peritumoral vessel invasion unknown (n=469) 35 L, 33 T 0.97 0.60 to 1.56
0.76
Age < 65 years (n=3,127)
Age  65 years (n=1,795)
146 L, 164 T
157 L, 174 T 0.81
0.81 0.64 to 1.01
0.65 to 1.01
0.98
Other* (n=749)
ER+/PgR+, locally defined (n=3,024)
ER+/PgR- or ER-/PgR+, locally defined (n=1,149)
153 L, 158 T
78 L, 93 T
72 L, 87 T 0.71
0.83
0.87 0.70 to 1.08
0.61 to 1.12
0.51 to 0.97
0.57
Node positive (n=2,067) 191 L, 218 T 0.75 0.61 to 0.91
Node negative, including Nx/unknown (n=2,855) 112 L, 120 T 0.91 0.70 to 1.17 0.24
Tumor grade 2 (n=2,324) 121 L, 154 T 0.68 0.54 to 0.87
Tumor grade 3 (n=621) 61 L, 56 T 1.12 0.77 to 1.62
Tumor grade unknown (n=706) 79 L, 69 T 0.99 0.71 to 1.37
Tumor grade 1 (n=1,271) 42 L, 59 T 0.69 0.46 to 1.02 0.07
Disease-free survival (DFS) 509 L, 544 T 0.83 0.74 to 0.94
Time to distant recurrence (TDR) 257 L, 292 T 0.80 0.67 to 0.94
Overall survival (OS) 303 L, 338 T 0.82 0.70 to 0.95
Overall (n=4,922) 303 L, 338 T 0.82 0.70 to 0.95
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Page 4 of 16(HR = 1.05, 99% CI 0.84 to 1.32) nor letrozole followed by 
tamoxifen (HR = 0.96, 99% CI 0.76 to 1.21) signiﬁ  cantly 
improved DFS compared with letrozole monotherapy 
(Figure 3). Women assigned tamoxifen followed by letro-
zole had a greater incidence of early relapses than those 
assigned letrozole monotherapy. Sequential treatment 
regimens with letrozole and tamoxifen did not improve 
DFS compared with letrozole monotherapy (Figure 3). 
Th  e estimated 5-year DFS percentages for the three 
letrozole-containing regimens of the sequential treatment 
analysis population are 87.9%, 87.6%, and 86.2% for 
letrozole monotherapy, letrozole followed by tamoxifen, 
and tamoxifen followed by letrozole groups, respectively. 
Th  ese  diﬀ  erences are not statistically signiﬁ  cant.
Translational research
As early as 2006, the BIG 1-98 database was used to 
identify prognostic factors for breast cancer relapse. 
Using the primary core analysis database [1] and Cox 
proportional hazards regression, we analyzed all eligible 
patients treated on BIG 1-98 and evaluated factors 
predictive of early relapse (within 2 years from random 
Figure 3. Cox model results for the sequential treatments (four-arm option) compared with letrozole monotherapy at median 
follow-up of 71 months. (a) Tamoxifen followed by letrozole versus letrozole monotherapy. (b) Letrozole followed by tamoxifen versus letrozole 
monotherapy. Both analyses were stratifi  ed for chemotherapy use. The size of the boxes is inversely proportional to the standard error of the hazard 
ratio. As specifi  ed in the protocol to account for multiple comparisons, 99% confi  dence intervals are shown. Results are shown for the disease-
free survival, overall survival, and time to distant recurrence endpoints. Interaction tests between treatment and nodal status are not statistically 
signifi  cant. CI, confi  dence interval; Let, letrozole; Nx, regional lymph nodes not examined; Tam, tamoxifen. Reprinted with permission from The New 
England Journal of Medicine [12]. Copyright 2009, Massachusetts Medical Society.
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Page 5 of 16assignment). Locally determined predictive factors for 
early relapse were node positivity, negative or missing 
estrogen receptor (ER) or progesterone receptor (PgR), 
high tumor grade, HER2 overexpression/ampliﬁ  cation, 
large tumor size, treatment with tamoxifen monotherapy, 
and peritumoral vascular invasion. Up  front letrozole 
resulted in signiﬁ   cantly fewer early relapses than 
tamoxifen, even after adjusting for signiﬁ    cant prognostic 
factors. Th  ese  early  ﬁ  ndings [18] helped set the stage for 
future translational research.
In 2005, the International Breast Cancer Study Group 
(IBCSG) Central Pathology Laboratory, recognizing the 
impor  tance of accurate assessment of the molecular 
targets that might predict the better treatment, began 
collecting formalin-ﬁ  xed,  paraﬃ   n-embedded  tumor 
blocks or, if these were not available, unstained slides for 
the assessment of ER, PgR, HER2, and Ki-67 labeling 
index (LI). Th  e material was reviewed for histopatho-
logical features and expression of tumor biomarkers 
without knowledge of patients’ treatment assignment or 
outcome. Th  e ﬁ   rst reports using these assessments 
focused on comparing letrozole and tamoxifen mono-
therapy by using the database reported at median follow-
up of 51 months [2].
Role of accurate assessment of steroid hormone receptor 
status
Th  e ﬁ  rst translational analysis focused on the primary 
target for endocrine treatment, steroid hormone recep-
tors. To be enrolled in BIG 1-98, the primary tumor had 
to be determined by local pathologists prior to random 
assignment to be positive for ER or PgR.
Th   e impact and importance of central assessment of ER 
and PgR for patients receiving monotherapy were 
reported in 2007 [19]. Local assessment for eligibility 
classiﬁ  ed 99.9% of enrolled patients as having hormone 
receptor-positive disease. Central assessment using 
immunohistochemistry (IHC) of 6,291 tumors classiﬁ  ed 
97.0% as positive (ER or PgR levels (or both) of at least 
10%). Monotherapy cohort patients whose tumors were 
classiﬁ  ed locally as hormone receptor-positive and re-
classiﬁ  ed as hormone receptor-negative by central review 
had worse outcomes, with estimated 65% 3-year DFS 
compared with 91% among patients whose tumors were 
classiﬁ  ed concordantly as positive (Figure 4).
Development of the Subpopulation Treatment Eff  ect 
Pattern Plot
A key analysis tool for determining the importance of 
these continuous-value biomarkers (such as level of ER 
staining) for determining treatment eﬀ  ectiveness is the 
Subpopulation Treatment Eﬀ   ect Pattern Plot (STEPP) 
[20]. STEPP was speciﬁ   cally developed for exploring 
patterns of treatment outcome diﬀ  erences  across 
sub  popu  lations of patients deﬁ   ned according to 
overlapping intervals of the biomarker values. Th  e  STEPP 
graphical presentation provides an overview of outcomes 
according to all values of a biomarker and can be used in 
addition to comparing treatments within subgroups 
based on estab  lished or arbitrarily deﬁ  ned  cutpoints 
(Figures 5 and 6).
PgR and HER2 as predictive factors for letrozole versus 
tamoxifen monotherapy
Central assessment of ER, PgR, and HER2 status was 
evaluable for 3,650 patients (74%) from the monotherapy 
arms [19,21]. Note that these patients were treated prior 
to the availability of trastuzumab for HER2-positive 
tumors. Tumors were considered HER2-positive if ampli-
ﬁ  ed by ﬂ  uorescence in situ hybridization (FISH) (gene-
to-chromosome 17 ratio of at least 2.0) or if staining 
intensity was 3+ by IHC (circumferential and intense 
membrane staining of greater than 10% invasive tumor 
cells) in the few tumors with unevaluable/unavailable 
FISH results. In tumors conﬁ  rmed to express ER, 10% 
had no PgR expression and 7% were HER2-positive. 
Alhough absence of PgR expression and HER2 positivity 
were each associated with poorer DFS, there remained a 
DFS advantage of letrozole for 5 years over tamoxifen for 
5 years irrespective of PgR or HER2 status [19,21]. Accor-
dingly, PgR or HER2 alone or together should not be used 
as discriminators in selecting initial adjuvant endocrine 
Figure 4. Disease-free survival according to central and 
local classifi  cation of hormone receptor status. Kaplan-Meier 
estimates at a median follow-up of 4 years for 3,610 patients on the 
monotherapy arms of Breast International Group 1-98 with adequate 
tumor material for central assessment of hormone receptors 
are shown. The two receptors are combined to defi  ne an overall 
assessment of hormone receptor status. Positive refers to estrogen 
receptor-positive or progesterone receptor-positive or both, and 
negative indicates that both are negative. DFS, disease-free survival; 
HR, hormone receptor; SE, standard error. Reprinted with permission 
from the Journal of Clinical Oncology [19]. Copyright 2007, American 
Society of Clinical Oncology.
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Page 6 of 16Figure 5. STEPP analysis of 5-year disease-free survival (DFS) 
according to level of centrally assessed tumor markers. 
(a) Estrogen receptor (ER) status, (b) progesterone receptor (PgR) 
status, (c) Ki-67 labeling index status, and (d) HER2 status for 5,177 
assessable patients enrolled in the four-arm option at a median follow-
up of 71 months. Rug plots along the x-axis display the distribution of 
individual values. Let, letrozole; STEPP, Subpopulation Treatment Eff  ect 
Pattern Plot; Tam, tamoxifen. Reprinted with permission from Annals of 
Oncology [23]. Copyright 2011, Oxford University Press.
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Page 7 of 16therapy for postmenopausal women with endocrine-
responsive early breast cancer.
Ki-67 labeling index as predictive factor for letrozole 
versus tamoxifen monotherapy
Among patients in the monotherapy analysis, 2,685 had 
primary tumor material available for central pathology 
assessment of Ki-67 LI by IHC and had tumors conﬁ  rmed 
to express ER after central review [22]. Higher values of 
Ki-67 LI were associated with poorer DFS, and there may 
be an interaction of Ki-67 LI with treatment as the 
magni  tude of the treatment beneﬁ  t for letrozole versus 
tamoxifen monotherapy was observed to be greater 
among patients with high-tumor Ki-67 LI than among 
those with low-tumor Ki-67 LI. In BIG 1-98, Ki-67 LI is a 
prognostic factor, and high Ki-67 LI levels may identify a 
patient group that particularly beneﬁ   ts from initial 
letrozole adjuvant therapy.
Composite risk assessment in the sequential treatment 
population
When the sequential treatment analysis was published 
[12], the IBCSG had collected and assessed additional 
tumor material for the four biomarkers. Th  e  investigation 
of the role of these biomarkers for the sequential treat-
ments (four-arm option) (Figure 1) included 5,177 patients 
(84%) with centrally conﬁ  rmed ER expression and other 
biomarkers available. Th  is analysis was based on the 
database used for the primary outcome of the sequential 
treatments at median follow-up of 71 months [12]. Th  is 
analysis also accounted for selective crossover.
We assessed whether centrally determined ER, PgR, 
and HER2 overexpression/ampliﬁ   cation and Ki-67 LI, 
alone or in combination with other prognostic features, 
predicted the magnitude of letrozole eﬀ  ectiveness com-
pared with either sequence or tamoxifen mono  therapy 
[23]. One motivation for this approach was that, despite a 
lack of data, a majority of the 2009 St. Gallen panelists 
preferred an initial aromatase inhibitor ‘particularly for 
patients at higher risk’ [11]. Second, in some settings, the 
cost and (for some patients) the side eﬀ  ects of aromatase 
inhibitor therapy make tamoxifen the preferable 
treatment. We therefore attemp  ted to examine whether 
clinical and pathological features can identify patient 
groups for whom it is more or less important that a 
5-year program include only or some aromatase inhibitor 
therapy.
Individually, none of the biomarkers signiﬁ  cantly 
predicted diﬀ  erential treatment eﬀ  ects among the treat-
ment groups (Figure 5). STEPP analysis of a composite 
measure of prognostic risk – which was based on an 
individual’s number of involved lymph nodes, tumor 
grade, tumor size, presence of peritumoral vascular 
invasion as determined by local pathology, plus age and 
the four centrally assessed tumor biomarkers – revealed 
three patterns of treatment eﬀ  ects (Figure 6b). Patients at 
highest risk did best when treated with 5 years of 
letrozole; any of the three letrozole-containing regimens 
was acceptable for those patients in an intermediate-risk 
range; whereas patients at lowest risk did similarly well 
with letrozole monotherapy, a sequence of letrozole and 
tamoxifen, or tamoxifen monotherapy. Th   us, in BIG 1-98, 
we conﬁ  rmed that the principle of composite assessment 
of risk, analogous to the clinical practice of integrating 
multiple risk factors when physicians and patients are 
deciding on the best adjuvant endocrine treatment for 
the individual patient, informs treatment selection better 
Figure 6. STEPP analysis of 5-year disease-free survival 
according to level of composite measure of prognostic risk. 
Plots include the 5,177 assessable patients enrolled in the four-arm 
option at a median follow-up of 71 months. (a) Treatment groups 
combined and (b) according to randomized treatment group. Rug 
plots along the x-axis display the distribution of individual values. 
DFS, disease-free survival; Let, letrozole; STEPP, Subpopulation 
Treatment Eff  ect Pattern Plot; Tam, tamoxifen. Reprinted with 
permission from Annals of Oncology [23]. Copyright 2011, Oxford 
University Press.
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Page 8 of 16than individual biomarkers and supports the choice of 
5 years of letrozole for patients at the highest risk for 
recurrence.
Future translational research
With the collection of over 5,000 tumor blocks, the 
IBCSG Central Pathology Oﬃ   ce was able to create tissue 
micoarrays to facilitate future research. Recent improve-
ments in the extraction of DNA and RNA from formalin-
ﬁ  xed,  paraﬃ     n-embedded tumor blocks enable the 
investi  gation of molecular features of the tumor and 
these features may predict a better patient outcome from 
endocrine therapy strategies. Plans are under way to 
investigate disease-related features, such as polymor-
phisms in or gene expression of ER-related genes, and 
patient-related features, such as polymorphisms in genes 
related to tamoxifen or aromatase inhibitor metabolism.
Th  e ﬁ  rst of these investigations evaluated the clinical 
relevance of cytochrome P450 2D6 (CYP2D6). Polymor-
phisms leading to reduced CYP2D6 enzyme activity may 
result in lower plasma concentrations of tamoxifen’s 
clinically active metabolite endoxifen, and this may in 
turn adversely impact the eﬃ   cacy of tamoxifen. Because 
of conﬂ  icting results of several small studies that investi-
gated the relation of CYP2D6 polymorphisms with 
clinical outcomes, whether polymorphisms that result in 
phenotypes of reduced enzyme activity are in fact 
associated with poorer disease control among tamoxifen-
treated patients is not clear. Results based on genotyping 
CYP2D6 polymorphisms among almost 5,000 BIG 1-98 
patients were presented at the San Antonio Breast Cancer 
Symposium in December 2010 [24] and a manuscript is 
in preparation.
Side eff  ects
For patients undergoing study drug administration, AEs 
were recorded at each 6-month follow-up visit by using 
check boxes on the case report forms. Severity was 
classiﬁ  ed according to National Cancer Institute Common 
Toxicity Criteria Version 2.0. Th   e relationship of the AE 
to study treatment was assessed by the local investigator. 
Targeted AEs that were explicitly collected were cardio-
vascular events (that is, myocardial infarction, cerebro-
vascular accident, transient ischemic attack, angina 
requiring percutaneous luminal coronary angioplasty or 
coronary artery bypass graft, thromboembolic event, 
hypercholesterolemia (cholesterol values reported, mostly 
non-fasting), and ‘other’), bone fractures, vaginal bleed-
ing, endometrial pathology, nausea, vomiting, hot ﬂ  ushes, 
night sweats, and events leading to therapy dis  con-
tinuation. Other cardiovascular AEs were collected by 
using an open-text comment ﬁ  eld for speciﬁ  cation by the 
investigator. Open-text ﬁ  elds were coded according to the 
Medical Dictionary for Regulatory Activities (MedDRA), 
and MedDRA preferred term [25] codes were further 
grouped into categories by IBCSG oncologists.
Senior oncologists at the IBCSG Coordinating Center, 
who were blinded to treatment assignment, reviewed all 
grade 3, 4, or 5 cardiovascular AEs; other grade 3 to 5 
AEs whose causes were unclear; and all deaths occurring 
prior to a DFS event. Pre-existing cardiovascular mor-
bidi  ties reported at the time of enrollment were also 
medically reviewed. A report of the cardiovascular side 
eﬀ  ects following this extensive review was published in 
2007, documenting a low overall cardiovascular AE 
incidence that diﬀ  ered between monotherapy treatment 
arms [26]. Th  e incidence of hypertension or cerebro-
vascular events was similar as was the overall incidence 
of cardiac AEs, although there were more grade 3 to 5 
cardiac AEs on letrozole; this excess was only partially 
attributable to prior hypercholesterolemia. Th  ere were 
more overall and grade 3 to 5 thromboembolic AEs on 
tamoxifen. Th  e incidence of AEs has been updated 
through a median follow-up of 76 months (Figure 7).
In addition, several focused reports on the safety of 
letrozole and tamoxifen in BIG 1-98, including bone 
events [27] in all patients and AEs in elderly patients [28], 
have been published. Consistent with other reports of 
aromatase inhibitors, the incidence of bone fractures was 
higher among patients treated with letrozole versus 
tamoxifen. Th  e wrist was the most common site of 
fracture in both treatment groups. Risk factors for bone 
fractures during treatment included age, smoking history, 
osteoporosis at baseline, previous bone fracture, and 
previous hormone replacement therapy. Eﬃ   cacy results 
were similar for all age groups, including the 6% of 
‘elderly’ patients (over age 75 years) who were less likely 
to complete 5 years of either trial treatment. Incidence of 
bone fractures did not diﬀ   er by age. Among elderly 
patients, letrozole had a signiﬁ  cantly higher incidence of 
any grade 3 to 5 protocol-speciﬁ   ed non-fracture AE 
compared with tamoxifen, but diﬀ   erences were not 
signiﬁ  cant for thrombo  embolic or cardiac AEs. On the 
basis of a small number of patients older than 75 years, 
age per se should not be the only consideration for the 
choice of adjuvant endocrine therapy.
Detailed AE results comparing the entire 5-year treat-
ment period for all four treatments [12] and for the 
mono  therapy cohort [13] have been published. As 
previously reported, patients on tamoxifen experienced 
greater incidences of thromboembolic events, vaginal 
bleeding, hot ﬂ   ushes, and night sweats. Patients on 
letrozole experienced greater incidences of vaginal 
dryness, bone fractures, osteoporosis, and arthralgia/
myalgia (Figure 7a) and higher-grade cardiac events 
(Figure 7b). It is important to note that these analyses 
present the incidence of AEs for one regimen (letrozole) 
compared with the other (tamoxifen), and it is possible 
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cardiac or bone events [29,30]. Th   e incidences of the AEs 
occurring in the sequential arms generally show results 
similar to those of the monotherapies during the time the 
patient was on the individual agents (that is, ﬁ  rst 2 years 
or last 3 years) [12]. Figure 8 shows Kaplan-Meier 
Figure 7. Forest plot showing the relative risk of an adverse event. Grades 1 to 5 (a) and grades 3 to 5 (b) among the 4,895 patients who were 
assigned tamoxifen or letrozole monotherapy and who received some trial treatment. All patients had completed treatment (median follow-up of 
76 months). AE, adverse event; CI, confi  dence interval; CVA/TIA, cerebral vascular accident/transient ischemic attack; MedDRA, Medical Dictionary 
for Regulatory Activities.
Adverse Event Tamoxifen (N=2447)
Natural Log of
Relative Risk (95% CI)
A-Grades 1-5
Myalgia* 172 (7.0%)
Arthralgia* 406 (16.6%)
Osteoporosis* 54 (2.2%)
Bone Fractures 165 (6.7%)
Night Sweats 418 (17.1%)
Hot Flushes 925 (37.8%)
Vaginal Dryness* 37 (1.5%)
Vaginal Bleeding 222 (9.1%)
Hypertension* 130 (5.3%)
Other Cardiac* 13 (0.5%)
Cardiac Failure* 25 (1.0%)
Ischemic heart disease 49 (2.0%)
Cardiac Event 152 (6.2%)
CVA/TIA 38 (1.6%)
Nausea/Vomiting 263 (10.7%)
Thromboembolic Event 104 (4.3%)
Events (%)
B-Grades 3-5
Myalgia* 13 (0.5%)
Arthralgia* 31 (1.3%)
Osteoporosis* 5 (0.2%)
Bone Fractures 43 (1.8%)
Hypertension* 41 (1.7%)
Cardiac Failure* 12 (0.5%)
Ischemic heart disease 25 (1.0%)
Cardiac Event 51 (2.1%)
CVA/TIA 38 (1.6%)
Thromboembolic Event 53 (2.2%)
Vaginal Bleeding 6 (0.2%)
Other Cardiac*
Letrozole (N=2448)
206 (8.4%)
551 (22.5%)
124 (5.1%)
244 (10.0%)
354 (14.5%)
820 (33.5%)
88 (3.6%)
104 (4.2%)
132 (5.4%)
24 (1.0%)
30 (1.2%)
69 (2.8%)
169 (6.9%)
45 (1.8%)
280 (11.4%)
63 (2.6%)
17 (0.7%)
50 (2.0%)
10 (0.4%)
84 (3.4%)
43 (1.8%)
21 (0.9%)
48 (2.0%)
93 (3.8%)
45 (1.8%)
31 (1.3%)
1 (0.0%)
3 (0.1%) 1 (0.0%)
More Tamoxifen AEs More Letrozole AEs
– 2 – 1 1 0 2
0.1 0.4 2.7 1.0  7.4
Natural Log of Relative Risk
Relative Risk Equivalent
*Collected as “other AE” or “other 
  cardiovascular AE” and coded 
  according to MedDRA.
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occurrence of four targeted AEs. Th   e incidence rates of 
cardiac events, thromboembolic events, and bone 
fractures or severe osteoporosis (Figure 8a-c) were 
relatively constant throughout follow-up. In contrast, 
24% of women taking letrozole and 29% taking tamoxifen 
reported hot ﬂ  ushes/night sweating within the ﬁ  rst year 
of therapy, with the incidence rates gradually decreasing 
over time (Figure 8d) [12].
Cognitive function substudy
In this substudy, cognitive function assessments were 
completed at the end of treatment (5 years) and about 
1  year later (6 years). Th  e 5-year analysis showed that 
cognitive function was signiﬁ   cantly better among the 
patients who were receiving letrozole at the end of the 
5-year treatment period in comparison with those 
receiving tamoxifen [31]. A second analysis comparing 
the 5-year assessments of cognitive function with those 
collected about 1 year later showed a signiﬁ  cant 
improvement in cognitive function following completion 
of endocrine therapy for both treatment regimens; the 
magnitude of improvement was not signiﬁ  cantly diﬀ  erent 
between treatments [32].
Discussion
Th  e BIG 1-98 trial was designed to compare 5 years of 
tamoxifen with 5 years of the aromatase inhibitor 
letrozole and to compare the strategy of the sequential 
treatments with the monotherapy approach. Twelve years 
after the ﬁ  rst patient was entered, these goals have been 
met. During these 12 years, evolving data from other 
Figure 8. Kaplan-Meier cumulative incidence estimates of time to fi  rst occurrence of four targeted adverse events. Cumulative incidence 
estimates of (a) cardiac events (any grade), (b) thromboembolic events (any grade), (c) osteoporosis (grade 3) or bone fractures (any grade), 
and (d) hot fl  ushes or night sweats (any grade) are shown. Letrozole is compared with tamoxifen among the 4,895 patients who were assigned 
tamoxifen or letrozole monotherapy and who received some trial treatment. All patients had completed treatment (median follow-up of 
76 months). AE, adverse event. Reprinted with permission from the Journal of Clinical Oncology [13]. Copyright 2011, American Society of Clinical 
Oncology.
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Page 11 of 16trials and the selective crossover of one quarter of the 
tamoxifen-treated patients to a more eﬀ  ective treatment 
in this trial led to the adaptation of analysis plans to 
present the most accurate and clinically useful long-term 
results to the oncology community.
Although all of the patients have completed protocol 
treatment, BIG 1-98 continues to provide useful infor-
mation beyond the primary questions of eﬃ   cacy.  Th  e 
translational reports on known biomarkers and the 
composite assessment obtained by putting the available 
tumor characteristics together to assess the risk of 
recurrence provide a basis on which to make informed 
patient treatment selection decisions. Future translational 
research will assess, for example, outcome according to 
CYP2D6, further clarifying individual patient diﬀ  erences 
that may be used to make treatment decisions. Th  e 
detailed safety data from this study also provide infor-
mation that can be used to assist in treatment selection. 
Th  ese data are reassuring for the average patient, and 
certain patient co-morbidities and conditions should be 
considered in weighing the treatment options.
Conclusions
In all reports of this trial, the authors have attempted to 
present a clear interpretation of the treatment compari-
sons for both the average and the individual patient. 
Reports to date have presented the most clinically 
meaningful analyses and interpretations. Th  e enhanced 
study design has enabled the presentation of two research 
questions from a single trial, thus saving time and money. 
On average, letrozole improves DFS, TDR, and OS in 
comparison with tamoxifen. Neither sequence of treat-
ments improves results over letrozole monotherapy. 
However, there may be groups of patients (for example, 
those at low or intermediate risk) for whom tamoxifen or a 
sequence of the two agents represents a reasonable choice.
Th  ere is no single interpretation of this trial, but for 
postmenopausal women with endocrine-responsive early 
breast cancer, BIG 1-98 results can be used to weigh the 
risks and beneﬁ  ts of the various treatment options in 
terms of eﬃ   cacy  in  tumor-deﬁ   ned subgroups, AEs 
observed among 8,000 women, and tumor biology not 
yet determined.
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